However, 15-30% of patients with acute pericarditis develop recurrent pericarditis

Recurrent pericarditis (RP) is the recurrence of pericarditis after a more than 4-6 week symptom-free period. RP is typically treated with steroids, colchicine, NSAIDs. Nevertheless, RP is associated with a high burden of disease and there is an unmet need for better treatment.

The highlight of the last day of #ACR19 is the Rheumatology Roundup Highlights #ACRBest by Drs. John Cush @RheumNow and Arthur Kavanaugh @ACRheum always worth attending with great take home messages #rheum https://t.co/eMdvc2byKG

Hope to have many more interdisciplinary discussions re. irAEs #ACR19 @LCalabreseDO @CCalabreseDO @EladSharonMD @DrJNaidoo @UmaThanaMD @lexmeara @drdavidliew https://t.co/8KDorKW2WJ

• Hopkins Med News on Twitter: "Laura Cappelli organized an open discussion …

Great ACR 2019. We weathered the weather #ACR @RheumNow https://t.co/lCKxADudRf

Different centres have different yields from temporal artery biopsy independent of biopsy length #ACR19 @RheumNow Abs 2685 https://t.co/Gqy9sY4OrM

Just took few pictures during social media gathering yesterday at #ACR19. It was so nice to meet everyone. Thanks to @psufka for organizing and it was nice to meet the man behind the legend! @Drbeckyg @maio_danila https://t.co/lSpPz0V4ng

Therapeutic approach to skin in #Scleroderma #ACR19 https://t.co/ZV8J5Z0wum

Couldn’t be explained better https://t.co/m7qmeWCLnl

• Jonathan Hausmann MD on Twitter: "BENEFITS OF E-POSTERS:
- No need to …

Myositis Treatment Pearls - Optimize drug dose and allow adequate time to reach effectiveness - Steroids NOT always necessary - Steroids and IVIG are the fastest acting agents - Reasons for admission: dysphagia and SOB

Primary care providers - take a look at these new gout guidelines. They're very straightforward, and your patients will do much better than if you follow the ACP guidelines. #ACR19 https://t.co/BIGLj6GKRe

• Mike Putman on Twitter: "All the NEW Clinical Practice Guidelines for GOUT…

Hello #ACR19. Are you still confused 😲 about the #pathways of #JAK-inhibitors and #Interferon-blocking strategies in #Lupus? Check up this refresher slide showing what these #SLE #treatments target!! 🎯 https://t.co/ZNnJTkz4nK

That’s a wrap on #ACR2019 ! Check out @RheumNow for meeting coverage, and see you next year in DC! @LCalabreseDO #cleclinicrheum https://t.co/sx2M5sD6pU

Never thought I'd say it. ACR in beautiful Atlanta. Kind of grows on you. #ACR #ACR19 @RheumNow https://t.co/YJOi5lEQei

My post on @RheumNow: “Muscle loss and frailty in rheumatic disease" https://t.co/lpTBAPkrbV #ACR19

• Muscle Loss and Frailty in Rheumatic Disease | ACR19 Coverage by RheumNow